AbCellera, Gilead collaborate for new multi-year, multi-target antibody discovery
Expanded collaboration includes an eight-target discovery partnership leveraging AbCellera’s entire technology stack
AbCellera announced agreements to expand its collaboration with Gilead Sciences including a multi-year, multi-target antibody discovery collaboration and access to AbCellera’s humanised mouse technology, the Trianni Mouse. Under the financial terms of the agreements, AbCellera will receive an upfront payment and is eligible for milestone payments and royalties based on the development and commercialisation of antibodies generated by AbCellera under this collaboration.
Building on the successful completion of the first collaboration together, under the new agreement AbCellera will generate panels of antibodies for up to eight new targets, across multiple indications, selected by Gilead. The expanded collaboration will leverage the full breadth of AbCellera’s technology stack, including the recently added capabilities for sourcing diverse, fully-humanised antibodies using the Trianni Mouse platform and combining any two antibodies to create native bispecifics using the OrthoMab protein engineering platform.